Hyderabad, Mar 24 (UNI) Suven Life Sciences Ltd today announced that product patents were granted in Eurasia for two of their New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases.
These patents were valid in all contracting countries like Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan till 2023, a press release said here.
These patents are exclusive intellectual property of Suven and achieved through exclusive internal discovery research efforts.
Products out of these inventions which are in pre-clinical development may be out-licensed at the stage of Clinical Phase-I or Phase-II stage.
''We are very pleased by the issuance of these patents to Suven for our drug candidates that are being developed for CNS disorders which targets an 18 billion US Dollar potential market opportunity globally,'' Suven CEO Venkat Jasti said.
UNI VA GM AK1423